Group effect in 2x2 BE study [Software]

posted by zan – US, 2014-06-30 21:18 (4365 d 06:30 ago) – Posting: # 13175
Views: 31,037

Thanks very much for the useful reply, ElMaestro and Helmut! Yes I am using Phoenix Winnonlin to work on this analysis. If there is a significant treatment*Group effect, is the overall (all subject) ratio (CI90%) still valid, or we have to adopt the ratio (CI90%) from separate groups?

Regarding FDA's requirement below (equiva­lence be demonstrated in one of the groups), do we have a link to the source of the letter? I am hoping to keep it as a reference for study files.

❝ If the Treatment-by-Group term is not significant (p ≥0.1) this term can be dropped from the model, proceeding to Group Model II.

❝ If the Treatment-by-Group term is significant (p <0.1), FDA’s Division of Bioequivalence requests that equiva­lence be demonstrated in one of the groups, provided that the group meets minimum requirements for a com­plete BE study (i.e., 12).


Best regards
zan

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
124 visitors (0 registered, 124 guests [including 48 identified bots]).
Forum time: 03:49 CEST (Europe/Vienna)

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5